294 related articles for article (PubMed ID: 26067933)
21. Characterization of CD34
Mayado A; Teodosio C; Dasilva-Freire N; Jara-Acevedo M; Garcia-Montero AC; Álvarez-Twose I; Sánchez-Muñoz L; Matito A; Caldas C; Muñoz-González JI; Henriques A; Sánchez-Gallego JI; Escribano L; Orfao A
Allergy; 2018 Jun; 73(6):1294-1304. PubMed ID: 29331029
[TBL] [Abstract][Full Text] [Related]
22. Standards of Genetic Testing in the Diagnosis and Prognostication of Systemic Mastocytosis in 2022: Recommendations of the EU-US Cooperative Group.
Hoermann G; Sotlar K; Jawhar M; Kristensen T; Bachelot G; Nedoszytko B; Carter MC; Horny HP; Bonadonna P; Sperr WR; Hartmann K; Brockow K; Lyons JJ; Kluin-Nelemans HC; Hermine O; Akin C; Broesby-Olsen S; Triggiani M; Butterfield JH; Schwaab J; Reiter A; Gotlib J; Metcalfe DD; George TI; Orfao A; Valent P; Arock M
J Allergy Clin Immunol Pract; 2022 Aug; 10(8):1953-1963. PubMed ID: 35283331
[TBL] [Abstract][Full Text] [Related]
23. Diagnosis of Primary Mast Cell Disorders in Anaphylaxis: Value of KIT D816V in Peripheral Blood.
De Puysseleyr LP; Ebo DG; Elst J; Faber MA; Poorten MV; Van Gasse AL; Bridts CH; Mertens C; Van Houdt M; Hagendorens MM; Verlinden A; Vermeulen K; Maes MB; Berneman ZN; Sabato V
J Allergy Clin Immunol Pract; 2021 Aug; 9(8):3176-3187.e3. PubMed ID: 33975032
[TBL] [Abstract][Full Text] [Related]
24. Detection of the c-kit D816V mutation in systemic mastocytosis by allele-specific PCR.
Schumacher JA; Elenitoba-Johnson KS; Lim MS
J Clin Pathol; 2008 Jan; 61(1):109-14. PubMed ID: 17526803
[TBL] [Abstract][Full Text] [Related]
25. Single-cell analysis reveals the KIT D816V mutation in haematopoietic stem and progenitor cells in systemic mastocytosis.
Grootens J; Ungerstedt JS; Ekoff M; Rönnberg E; Klimkowska M; Amini RM; Arock M; Söderlund S; Mattsson M; Nilsson G; Dahlin JS
EBioMedicine; 2019 May; 43():150-158. PubMed ID: 30975542
[TBL] [Abstract][Full Text] [Related]
26. The KIT D816V allele burden predicts survival in patients with mastocytosis and correlates with the WHO type of the disease.
Hoermann G; Gleixner KV; Dinu GE; Kundi M; Greiner G; Wimazal F; Hadzijusufovic E; Mitterbauer G; Mannhalter C; Valent P; Sperr WR
Allergy; 2014 Jun; 69(6):810-3. PubMed ID: 24750133
[TBL] [Abstract][Full Text] [Related]
27. Identification of oncostatin M as a STAT5-dependent mediator of bone marrow remodeling in KIT D816V-positive systemic mastocytosis.
Hoermann G; Cerny-Reiterer S; Perné A; Klauser M; Hoetzenecker K; Klein K; Müllauer L; Gröger M; Nijman SM; Klepetko W; Valent P; Mayerhofer M
Am J Pathol; 2011 May; 178(5):2344-56. PubMed ID: 21457934
[TBL] [Abstract][Full Text] [Related]
28. Comparison of gDNA-based versus mRNA-based KIT D816V mutation analysis reveals large differences between blood and bone marrow in systemic mastocytosis.
Kristensen T; Broesby-Olsen S; Vestergaard H; Bindslev-Jensen C; Møller MB;
Br J Haematol; 2017 Jul; 178(2):330-332. PubMed ID: 27196380
[No Abstract] [Full Text] [Related]
29. Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis.
Wilson TM; Maric I; Simakova O; Bai Y; Chan EC; Olivares N; Carter M; Maric D; Robyn J; Metcalfe DD
Haematologica; 2011 Mar; 96(3):459-63. PubMed ID: 21134978
[TBL] [Abstract][Full Text] [Related]
30. Histone deacetylase inhibitor SAHA mediates mast cell death and epigenetic silencing of constitutively active D816V KIT in systemic mastocytosis.
Lyberg K; Ali HA; Grootens J; Kjellander M; Tirfing M; Arock M; Hägglund H; Nilsson G; Ungerstedt J
Oncotarget; 2017 Feb; 8(6):9647-9659. PubMed ID: 28038453
[TBL] [Abstract][Full Text] [Related]
31. Adverse Prognostic Impact of the
Naumann N; Lübke J; Baumann S; Schwaab J; Hoffmann O; Kreil S; Dangelo V; Reiter L; Bugert P; Kristensen T; Sotlar K; Haselmann V; Schneider S; Metzgeroth G; Weiss C; Popp HD; Fabarius A; Hofmann WK; Cross NCP; Reiter A; Jawhar M
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33806359
[TBL] [Abstract][Full Text] [Related]
32. Systemic mastocytosis associated with chronic idiopathic myelofibrosis: a distinct subtype of systemic mastocytosis associated with a [corrected] clonal hematological non-mast [corrected] cell lineage disorder carrying the activating point mutations KITD816V and JAK2V617F.
Sotlar K; Bache A; Stellmacher F; Bültmann B; Valent P; Horny HP
J Mol Diagn; 2008 Jan; 10(1):58-66. PubMed ID: 18165278
[TBL] [Abstract][Full Text] [Related]
33. Sensitive KIT D816V mutation analysis of blood as a diagnostic test in mastocytosis.
Kristensen T; Vestergaard H; Bindslev-Jensen C; Møller MB; Broesby-Olsen S;
Am J Hematol; 2014 May; 89(5):493-8. PubMed ID: 24443360
[TBL] [Abstract][Full Text] [Related]
34. A transgenic zebrafish model expressing KIT-D816V recapitulates features of aggressive systemic mastocytosis.
Balci TB; Prykhozhij SV; Teh EM; Da'as SI; McBride E; Liwski R; Chute IC; Leger D; Lewis SM; Berman JN
Br J Haematol; 2014 Oct; 167(1):48-61. PubMed ID: 24989799
[TBL] [Abstract][Full Text] [Related]
35. KIT D816V mutation detection: a comparative study using peripheral blood, bone marrow aspirate and bone marrow trephine samples for detection of KIT mutations in patients with systemic mastocytosis.
Agarwal R; McBean M; Hewitt C; Westerman DA
Leuk Lymphoma; 2014 Sep; 55(9):2202-3. PubMed ID: 24359244
[No Abstract] [Full Text] [Related]
36. Proposed European Competence Network on Mastocytosis-American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic Mastocytosis.
Gotlib J; Schwaab J; Shomali W; George TI; Radia DH; Castells M; Carter MC; Hartmann K; Álvarez-Twose I; Brockow K; Bonadonna P; Hermine O; Niedoszytko M; Hoermann G; Sperr WR; Elberink HO; Siebenhaar F; Butterfield JH; Ustun C; Zanotti R; Triggiani M; Schwartz LB; Lyons JJ; Orfao A; Sotlar K; Horny HP; Arock M; Metcalfe DD; Akin C; Lübke J; Valent P; Reiter A
J Allergy Clin Immunol Pract; 2022 Aug; 10(8):2025-2038.e1. PubMed ID: 35724948
[TBL] [Abstract][Full Text] [Related]
37. Recent Advances in the Molecular Biology of Systemic Mastocytosis: Implications for Diagnosis, Prognosis, and Therapy.
Martelli M; Monaldi C; De Santis S; Bruno S; Mancini M; Cavo M; Soverini S
Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32498255
[TBL] [Abstract][Full Text] [Related]
38. KIT GNNK splice variants: expression in systemic mastocytosis and influence on the activating potential of the D816V mutation in mast cells.
Chan EC; Bai Y; Bandara G; Simakova O; Brittain E; Scott L; Dyer KD; Klion AD; Maric I; Gilfillan AM; Metcalfe DD; Wilson TM
Exp Hematol; 2013 Oct; 41(10):870-881.e2. PubMed ID: 23743299
[TBL] [Abstract][Full Text] [Related]
39. Systemic mastocytosis involving the gastrointestinal tract: clinicopathologic and molecular study of five cases.
Kirsch R; Geboes K; Shepherd NA; de Hertogh G; Di Nicola N; Lebel S; Mickys U; Riddell RH
Mod Pathol; 2008 Dec; 21(12):1508-16. PubMed ID: 18931652
[TBL] [Abstract][Full Text] [Related]
40. Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event.
Jawhar M; Schwaab J; Schnittger S; Sotlar K; Horny HP; Metzgeroth G; Müller N; Schneider S; Naumann N; Walz C; Haferlach T; Valent P; Hofmann WK; Cross NC; Fabarius A; Reiter A
Leukemia; 2015 May; 29(5):1115-22. PubMed ID: 25567135
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
